This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM

By: Adam Feuerstein | 03/26/14 - 05:14 PM EDT

Stocks in this article: NVSARIA

This week's issue of the New England Journal of Medicine includes a study of Novartis' (NVS) ALK-inhibitor ceritinib demonstrating strong activity in ALK-positive non-small cell lung cancer, including patients previously treated with Pfizer's (PFE) Xalkori, another ALK-inhibitor. An editorial supportive of ceritinib accompanies the study publication in the same NEJM issue. 

Novartis has already submitted ceritinib (also known as LDK378) to the FDA for approval, although the company has not disclosed an approval decision date. Approximately 5% of lung cancers involve tumors with alternations to the ALK gene.

Ariad Pharmaceuticals (ARIA) is developing its own ALK inhibitor AP26113 in lung cancer, but a pivotal study was just started so the company is significantly behind Novartis.

The Novartis study enrolled patients with non-small cell lung cancer which harbored genetic alterations to the ALK gene. Among 114 patients who received at least 400 mg of ceritinib per day, the overall response rate was 58%. Among a subset of patients treated with Pfizer's Xalkori previously, the response rate was 56%. The median progression-free survival was 7 months, according to the NEJM publication. 

"This suggests that in patients with ALK-rearranged NSCLC, a more potent and specific ALK inhibitor can effectively treat the majority of patients in whom resistance to crizotinib develops," the ceritinib study authors conclude.

The safety profile of ceritinib was found to be similar to Xalkori, except for higher rates of diarrhea and nausea.

Here's how the NEJM editorial sums up the ceritinib data:

"The study by Shaw and colleagues is good news for patients with ALK -rearranged lung cancer. It is also an example of how mechanistically inspired and rationally designed trials involving large, genotypically defined patient cohorts can lead to dramatic steps forward in the care of patients with cancer."

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs